EE03031B1 - Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid - Google Patents
Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonidInfo
- Publication number
- EE03031B1 EE03031B1 EE9400328A EE9400328A EE03031B1 EE 03031 B1 EE03031 B1 EE 03031B1 EE 9400328 A EE9400328 A EE 9400328A EE 9400328 A EE9400328 A EE 9400328A EE 03031 B1 EE03031 B1 EE 03031B1
- Authority
- EE
- Estonia
- Prior art keywords
- antigen
- monoclonal antibody
- carbogen
- tumor
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9102074A SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Tomour antigen specific antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
EE03031B1 true EE03031B1 (et) | 1997-08-15 |
Family
ID=20383243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9400328A EE03031B1 (et) | 1991-07-03 | 1994-11-16 | Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid |
Country Status (19)
Country | Link |
---|---|
US (1) | US5552293A (et) |
EP (1) | EP0521842B1 (et) |
JP (1) | JP3194020B2 (et) |
KR (1) | KR100246681B1 (et) |
AT (1) | ATE171193T1 (et) |
AU (2) | AU658198B2 (et) |
CA (1) | CA2073124C (et) |
DE (1) | DE69226990T2 (et) |
DK (1) | DK0521842T3 (et) |
EE (1) | EE03031B1 (et) |
ES (1) | ES2124250T3 (et) |
FI (1) | FI109207B (et) |
HU (2) | HU218084B (et) |
IE (1) | IE80841B1 (et) |
IL (1) | IL102390A (et) |
NO (1) | NO315472B1 (et) |
NZ (1) | NZ243435A (et) |
SE (1) | SE9102074D0 (et) |
WO (2) | WO1993001302A1 (et) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9402430L (sv) | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
ES2619313T3 (es) * | 2001-03-15 | 2017-06-26 | Precision Biologics, Inc. | Terapia de anticuerpos monoclonales para el cáncer de páncreas |
DE10116552A1 (de) * | 2001-04-03 | 2002-10-10 | Abc Armbruster Biochemicals | Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe |
US20060246060A1 (en) * | 2002-07-02 | 2006-11-02 | Nesta Douglas P | Novel stable formulation |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
CA2525130C (en) | 2003-05-20 | 2014-04-15 | Immunogen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
AU2006213662B2 (en) | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
AU2012244244B2 (en) * | 2005-08-11 | 2015-08-27 | Arpi Matossian-Rogers | TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease |
BRPI0614366A2 (pt) * | 2005-08-11 | 2009-10-06 | Arpi Matossian Rogers | peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos |
AU2006283726C1 (en) | 2005-08-24 | 2015-05-07 | Immunogen, Inc. | Process for preparing maytansinoid antibody conjugates |
ES2570731T3 (es) | 2008-08-05 | 2016-05-20 | Toray Industries | Método de detección de cáncer |
ES2726945T3 (es) | 2009-06-03 | 2019-10-10 | Immunogen Inc | Métodos de conjugación |
WO2012135517A2 (en) | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
ME03353B (me) | 2011-03-29 | 2019-10-20 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
NZ707091A (en) | 2012-10-04 | 2018-12-21 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
WO2015076425A1 (ja) * | 2013-11-25 | 2015-05-28 | リンク・ジェノミクス株式会社 | 新規モノクローナル抗体 |
MA40934A (fr) | 2014-11-19 | 2017-09-27 | Immunogen Inc | Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique |
AU2017206656B2 (en) | 2016-01-10 | 2024-02-01 | Neotx Therapeutics Ltd. | Immunopotentiator enhanced superantigen mediated cancer immunotherapy |
CN108601848A (zh) | 2016-02-05 | 2018-09-28 | 伊缪诺金公司 | 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法 |
CN107167590B (zh) * | 2017-04-14 | 2019-03-08 | 江苏福隆生物技术有限公司 | 糖类抗原242的板式化学发光法检测试剂盒及制备方法 |
WO2019035034A1 (en) * | 2017-08-16 | 2019-02-21 | The Broad Institute, Inc. | NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN |
WO2020230142A1 (en) | 2019-05-15 | 2020-11-19 | Neotx Therapeutics Ltd. | Cancer treatment |
AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4752569A (en) * | 1984-06-21 | 1988-06-21 | The Regents Of The University Of California | Sialylated Lewisx epitope, antibodies and diagnosis |
US4904596A (en) * | 1985-08-07 | 1990-02-27 | Fred Hutchinson Cancer Research Center | Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside |
SE8902043L (sv) * | 1988-11-10 | 1990-05-11 | Pharmacia Ab | Foerfarande foer karakterisering av makromolekyler |
WO1992001474A1 (en) * | 1990-07-20 | 1992-02-06 | Kabi Pharmacia Ab | Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
EP0610179B1 (en) * | 1990-07-20 | 1996-10-16 | Pharmacia AB (reg.number 556131-9608) | Target specific antibody-superantigen conjugates and their preparation |
-
1991
- 1991-07-03 SE SE9102074A patent/SE9102074D0/xx unknown
-
1992
- 1992-07-02 IL IL10239092A patent/IL102390A/en not_active IP Right Cessation
- 1992-07-02 WO PCT/SE1992/000495 patent/WO1993001302A1/en active Search and Examination
- 1992-07-03 AT AT92850166T patent/ATE171193T1/de not_active IP Right Cessation
- 1992-07-03 CA CA002073124A patent/CA2073124C/en not_active Expired - Lifetime
- 1992-07-03 WO PCT/SE1992/000502 patent/WO1993001303A1/en active IP Right Grant
- 1992-07-03 HU HU9400011A patent/HU218084B/hu not_active IP Right Cessation
- 1992-07-03 AU AU19425/92A patent/AU658198B2/en not_active Ceased
- 1992-07-03 ES ES92850166T patent/ES2124250T3/es not_active Expired - Lifetime
- 1992-07-03 JP JP17584892A patent/JP3194020B2/ja not_active Expired - Lifetime
- 1992-07-03 AU AU22920/92A patent/AU2292092A/en not_active Abandoned
- 1992-07-03 NZ NZ243435A patent/NZ243435A/en not_active IP Right Cessation
- 1992-07-03 EP EP92850166A patent/EP0521842B1/en not_active Expired - Lifetime
- 1992-07-03 DK DK92850166T patent/DK0521842T3/da active
- 1992-07-03 DE DE69226990T patent/DE69226990T2/de not_active Expired - Lifetime
- 1992-07-03 KR KR1019930704117A patent/KR100246681B1/ko not_active IP Right Cessation
- 1992-07-03 IE IE922188A patent/IE80841B1/en not_active IP Right Cessation
-
1993
- 1993-12-22 NO NO19934777A patent/NO315472B1/no unknown
- 1993-12-31 FI FI935970A patent/FI109207B/fi not_active IP Right Cessation
-
1994
- 1994-11-16 EE EE9400328A patent/EE03031B1/et not_active IP Right Cessation
-
1995
- 1995-05-08 US US08/438,123 patent/US5552293A/en not_active Expired - Lifetime
- 1995-06-20 HU HU95P/P00289P patent/HU211512A9/hu unknown
Also Published As
Publication number | Publication date |
---|---|
HUT71193A (en) | 1995-11-28 |
AU658198B2 (en) | 1995-04-06 |
IE922188A1 (en) | 1993-01-13 |
CA2073124C (en) | 2007-06-19 |
ATE171193T1 (de) | 1998-10-15 |
IL102390A0 (en) | 1993-01-14 |
NO934777L (no) | 1994-02-11 |
JP3194020B2 (ja) | 2001-07-30 |
HU211512A9 (en) | 1995-11-28 |
NZ243435A (en) | 1994-10-26 |
FI935970A (fi) | 1993-12-31 |
HU218084B (hu) | 2000-05-28 |
IL102390A (en) | 1996-01-19 |
HU9400011D0 (en) | 1994-05-30 |
WO1993001302A1 (en) | 1993-01-21 |
NO934777D0 (no) | 1993-12-22 |
US5552293A (en) | 1996-09-03 |
ES2124250T3 (es) | 1999-02-01 |
DK0521842T3 (da) | 1999-06-14 |
AU2292092A (en) | 1993-02-11 |
NO315472B1 (no) | 2003-09-08 |
EP0521842A2 (en) | 1993-01-07 |
FI109207B (fi) | 2002-06-14 |
KR100246681B1 (ko) | 2000-04-01 |
WO1993001303A1 (en) | 1993-01-21 |
JPH05276987A (ja) | 1993-10-26 |
DE69226990D1 (de) | 1998-10-22 |
AU1942592A (en) | 1993-01-07 |
FI935970A0 (fi) | 1993-12-31 |
EP0521842A3 (et) | 1994-01-26 |
EP0521842B1 (en) | 1998-09-16 |
DE69226990T2 (de) | 1999-03-25 |
IE80841B1 (en) | 1999-03-24 |
SE9102074D0 (sv) | 1991-07-03 |
CA2073124A1 (en) | 1993-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE03031B1 (et) | Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid | |
FI101937B1 (fi) | Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa | |
ATE13317T1 (de) | Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozytantigen; antikoerper und verfahren zu seiner herstellung; diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen. | |
EP0822830A4 (en) | HUMAN ANTIBODIES FROM IMMUNIZED XENOMAS | |
AU2097692A (en) | Method for the production of monoclonal antibodies utilizing a germfree animal | |
GR3020108T3 (en) | Monoclonal antibody reactive with a novel HLA determinant on MHC class I molecules and method for activating lymphocytes | |
JPS6447378A (en) | Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof | |
ATE113845T1 (de) | Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung. | |
DE3583265D1 (de) | Tumortherapeutikum und verfahren zu seiner herstellung. | |
DE69015230T2 (de) | Antikörper gegen menschliches Sperma, ihre Herstellung und Anwendung. | |
DE3688204T2 (de) | Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens. | |
DE3580524D1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. | |
RU93058456A (ru) | Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии | |
ATE243742T1 (de) | Hybridzelle und deren verwendung zur herstellung eines arzneimittels zur induktion einer tumorimmunität | |
BG51640A1 (en) | Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenous determinant, common for the strains " hantaan " and " bulgarian " of the virus of haemorrhagic fever with nephritic syndrome | |
BG51731A1 (en) | Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenic deternimant, common for the strains hantaan and finnish of the virus of haemorrhagic fever with nephritic syndrome | |
DK182188A (da) | Humant tumorassocieret antigen | |
IT8020164A0 (it) | Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina. | |
BG51639A1 (en) | Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20021231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20071116 |